Epirubicin hydrochloride API is the hydrochloride salt of epirubicin, a semi-synthetic anthracycline antineoplastic antibiotic that serves as the 4'-epimer of doxorubicin and is derived from daunorubicin. Its chemical name is (8S-cis)-10-[(3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione hydrochloride, with the molecular formula C27H29NO11·HCl and a molecular weight of 579.98. The active moiety is a red-orange hygroscopic powder that exerts its antitumor effects through multiple mechanisms, including intercalation of its planar rings between DNA base pairs to inhibit nucleic acid and protein synthesis, stimulation of topoisomerase II-mediated DNA strand breaks, and generation of cytotoxic free radicals via redox cycling.
The API is manufactured via a semi-synthetic process that begins with microbial fermentation of appropriate Streptomyces strains to produce daunorubicin or 4'-epi-daunorubicin precursors, followed by chemical modification to invert the stereochemistry at the 4' position of the daunosamine sugar moiety. Key steps include formation of bromo-ketal intermediates, hydrolysis, oxidation, and purification through ion-exchange resins in chloride form, followed by adsorption chromatography, concentration, and final crystallization of the hydrochloride salt under controlled pH and solvent conditions to achieve pharmacopeial purity and stability.
Epirubicin hydrochloride is indicated as a component of adjuvant therapy in patients with primary breast cancer and axillary lymph node involvement following surgical resection, where it is administered intravenously in combination regimens to reduce recurrence risk. It is also used in the treatment of advanced or metastatic breast cancer and other malignancies including gastric carcinoma, ovarian carcinoma, lung carcinoma, soft-tissue sarcomas, malignant lymphomas, and certain leukemias, with dosing individualized according to body surface area and hepatic function to balance efficacy against risks of myelosuppression and cumulative cardiotoxicity.
The global Epirubicin Hydrochloride API market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Epirubicin Hydrochloride API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Epirubicin Hydrochloride API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Asia Pacific market for Epirubicin Hydrochloride API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Epirubicin Hydrochloride API market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Epirubicin Hydrochloride API market include Synbias-Gemini, TAPI, MicroBiopharm Japan, Olon S.p.A., Sterling Biotech, Lunan Pharmaceutical, Zhejiang Hisun and DZD (Heze) Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Epirubicin Hydrochloride API market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Epirubicin Hydrochloride API and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Epirubicin Hydrochloride API sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Epirubicin Hydrochloride API market size, projected growth trends, production technologies, key applications, and end-use industries.
Epirubicin Hydrochloride API Segment by Company
- Synbias-Gemini
- TAPI
- MicroBiopharm Japan
- Olon S.p.A.
- Sterling Biotech
- Lunan Pharmaceutical
- Zhejiang Hisun
- DZD (Heze) Pharmaceutical
Epirubicin Hydrochloride API Segment by Type
- USP Grade
- EP Grade
- CP Grade
- JP Grade
- BP Grade
- Others
Epirubicin Hydrochloride API Segment by Application
- Injection
- Freeze-dried Powder Injection
Epirubicin Hydrochloride API Segment by Region
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Spain
- Netherlands
- Switzerland
- Sweden
- Poland
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- Taiwan
- Southeast Asia
- South America
- Brazil
- Argentina
- Chile
- Colombia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Türkiye
- GCC Countries
Study Objectives
- To analyze and research the global Epirubicin Hydrochloride API status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
- To present the key manufacturers, sales, revenue, market share, and Recent Developments.
- To split the breakdown data by regions, type, manufacturers, and Application.
- To analyze the global and key regions Epirubicin Hydrochloride API market potential and advantage, opportunity and challenge, restraints, and risks.
- To identify Epirubicin Hydrochloride API significant trends, drivers, influence factors in global and regions.
- To analyze Epirubicin Hydrochloride API competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
- This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Epirubicin Hydrochloride API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
- This report will help stakeholders to understand the global industry status and trends of Epirubicin Hydrochloride API and provides them with information on key market drivers, restraints, challenges, and opportunities.
- This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
- This report stays updated with novel technology integration, features, and the latest developments in the market.
- This report helps stakeholders to gain insights into which regions to target globally.
- This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Epirubicin Hydrochloride API.
- This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Epirubicin Hydrochloride API market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Epirubicin Hydrochloride API industry.
Chapter 3: Detailed analysis of Epirubicin Hydrochloride API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Epirubicin Hydrochloride API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Epirubicin Hydrochloride API in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
